抗体诱导治疗在肝移植中的应用进展  

Application of antibody induction therapy in liver transplantation

作　　者：马葵芬[1] 朱雪娟 吴寅[3] 陈泉金[1] 许小鑫 郭桂萍[3] 陆遥[3] Ma Kuifen;Zhu Xuejuan;Wu Yin;Chen Quanjin;Xu Xiaoxin;Guo Guiping;Lu Yao(Department of pharmacy,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China;Department of ICU,Hangzhou Hospital of Zhejiang General Team Hospital of Armed Police,Hangzhou 310051,China;Department of pharmacy,Xijing Hospital,the Fourth Military Medical University,Xi＇an 710032,China)

机构地区：[1]浙江大学医学院附属第一医院药剂科,杭州310003 [2]武警浙江省总队杭州医院重症监护室,杭州310051 [3]第四军医大学西京医院药剂科,西安710032

出　　处：《中华移植杂志（电子版）》2018年第2期80-85,共6页Chinese Journal of Transplantation(Electronic Edition)

基　　金：浙江省医药卫生科技计划项目(201826399)

摘　　要：应用生物蛋白制剂——抗体作为器官移植早期实施免疫抑制覆盖治疗的方法,可显著减少器官移植术后早期急性排斥反应的发生,且未显著增加移植后感染发生率,同时可延迟或减少CNI的应用,有利于保护肾功能、促进移植物功能恢复及受者长期存活。本文通过总结常见抗体免疫诱导剂的特点及作用机制,分析不同抗体诱导治疗应用于肝移植的临床获益与风险,为肝移植抗体诱导剂的合理使用提供参考。The application of biological protein preparation, antibody, as an immunosuppressive therapy during the early stage of organ transplantation,can significantly reduce the risk of early acute rejection after organ transplantation without increasing postoperative infection. In the meantime,it can also delay or reduce the use of CNI. These advantages mean this therapy is beneficial for protecting renal function,graft function recovery and the long-term survival of recipients. By summarizing the characteristics and mechanisms of the common antibody immunization inducers,this paper tries to analyze the clinical benefits and risks of different antibody induction therapy in liver transplantation,hoping to provide reference for rational use of antibody induction therapy in liver transplantation.

关 键 词：诱导治疗 抗体 肝移植 急性排斥反应 

分 类 号：R657.3[医药卫生—外科学]